Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax RateWages, Salaries and Other
Others
Ratios

Bicycle Therapeutics (BCYC) EBITDA (2018 - 2026)

Bicycle Therapeutics (BCYC) has disclosed EBITDA for 9 consecutive years, with -$62.6 million as the latest value for Q1 2026.

  • For Q1 2026, EBITDA changed 0.43% year-over-year to -$62.6 million; the TTM value through Mar 2026 reached -$222.8 million, down 9.29%, while the annual FY2025 figure was -$222.6 million, 32.8% down from the prior year.
  • EBITDA hit -$62.6 million in Q1 2026 for Bicycle Therapeutics, down from -$20.2 million in the prior quarter.
  • Across five years, EBITDA topped out at -$20.2 million in Q4 2025 and bottomed at -$80.9 million in Q2 2025.
  • Average EBITDA over 5 years is -$43.8 million, with a median of -$43.6 million recorded in 2023.
  • On a YoY basis, EBITDA climbed as much as 58.42% in 2025 and fell as far as 139.41% in 2025.
  • Bicycle Therapeutics' EBITDA stood at -$30.1 million in 2022, then tumbled by 76.92% to -$53.3 million in 2023, then grew by 8.89% to -$48.6 million in 2024, then surged by 58.42% to -$20.2 million in 2025, then plummeted by 210.08% to -$62.6 million in 2026.
  • According to Business Quant data, EBITDA over the past three periods came in at -$62.6 million, -$20.2 million, and -$59.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.